Search

Your search keyword '"Woods, R. L."' showing total 327 results
Start Over Author "Woods, R. L."
327 results on '"Woods, R. L."'

5. Higher testosterone is associated with higher HDL-cholesterol and lower triglyceride concentrations in older women: an observational study.

Author

Davis, S. R., Azene, Z. N., Tonkin, A. M., Woods, R. L., McNeil, J. J., and Islam, R. M.

Subjects
OLDER women, LIQUID chromatography-mass spectrometry, HDL cholesterol, TESTOSTERONE, SCIENTIFIC observation
Abstract

Copyright of Climacteric is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

9. Compliance-Adjusted Estimates of Aspirin Effects Among Older Persons in the ASPREE Randomized Trial

Author

Smith, C L, primary, Kasza, J, additional, Woods, R L, additional, Lockery, J E, additional, Kirpach, B, additional, Reid, C M, additional, Storey, E, additional, Nelson, M R, additional, Shah, R C, additional, Orchard, S G, additional, Ernst, M E, additional, Tonkin, A M, additional, Murray, A M, additional, McNeil, J J, additional, and Wolfe, R, additional

Published
2023
Full Text
View/download PDF

12. P4557Factors associated with treatment and control of hypertension in a healthy elderly population free of cardiovascular disease: a cross-sectional study

Author

Chowdhury, E, primary, Nelson, M R, additional, Ernst, M E, additional, Margolis, K L, additional, Beilin, L J, additional, Johnston, C I, additional, Murray, A M, additional, Woods, R L, additional, Wolfe, R, additional, Tonkin, A M, additional, Williamson, J D, additional, Stocks, N P, additional, McNeil, J, additional, and Reid, C, additional

Published
2019
Full Text
View/download PDF

13. P6362Impact of the 2017 AHA/ACC hypertension guideline on hypertension prevalence and cardiovascular risk factors in a healthy older cohort

Author

Chowdhury, E K, primary, Nelson, M R, additional, Ernst, M E, additional, Margolis, K L, additional, Beilin, L J, additional, Johnston, C I, additional, Murray, A M, additional, Woods, R L, additional, Wolfe, R, additional, Tonkin, A M, additional, Williamson, J D, additional, Stocks, N P, additional, McNeil, J, additional, and Reid, C, additional

Published
2019
Full Text
View/download PDF

21. Effect of Aspirin on Disability-free Survival in the Healthy Elderly.

Author

McNeil, J. J., Woods, R. L., Nelson, M. R., Reid, C. M., Kirpach, B., Wolfe, R., Storey, E., Shah, R. C., Lockery, J. E., Tonkin, A. M., Newman, A. B., Williamson, J. D., Margolis, K. L., Ernst, M. E., Abhayaratna, W. P., Stocks, N., Fitzgerald, S. M., Orchard, S. G., Trevaks, R. E., and Beilin, L. J.

Subjects
*ASPIRIN, *OLDER people, *DEMENTIA, *HEMORRHAGE, *PLACEBOS, *RESEARCH, *MORTALITY, *ORAL drug administration, *RESEARCH methodology, *PROGNOSIS, *DISEASE incidence, *EVALUATION research, *TREATMENT failure, *COMPARATIVE studies, *RANDOMIZED controlled trials, *PLATELET aggregation inhibitors, *SURVIVAL analysis (Biometry), *BLIND experiment, *INDEPENDENT living, *RESEARCH funding, *PEOPLE with disabilities, *LONGITUDINAL method
Abstract

Background: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.Methods: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or physical disability. Participants were randomly assigned to receive 100 mg per day of enteric-coated aspirin or placebo orally. The primary end point was a composite of death, dementia, or persistent physical disability. Secondary end points reported in this article included the individual components of the primary end point and major hemorrhage.Results: A total of 19,114 persons with a median age of 74 years were enrolled, of whom 9525 were randomly assigned to receive aspirin and 9589 to receive placebo. A total of 56.4% of the participants were women, 8.7% were nonwhite, and 11.0% reported previous regular aspirin use. The trial was terminated at a median of 4.7 years of follow-up after a determination was made that there would be no benefit with continued aspirin use with regard to the primary end point. The rate of the composite of death, dementia, or persistent physical disability was 21.5 events per 1000 person-years in the aspirin group and 21.2 per 1000 person-years in the placebo group (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11; P=0.79). The rate of adherence to the assigned intervention was 62.1% in the aspirin group and 64.1% in the placebo group in the final year of trial participation. Differences between the aspirin group and the placebo group were not substantial with regard to the secondary individual end points of death from any cause (12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group), dementia, or persistent physical disability. The rate of major hemorrhage was higher in the aspirin group than in the placebo group (3.8% vs. 2.8%; hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001).Conclusions: Aspirin use in healthy elderly persons did not prolong disability-free survival over a period of 5 years but led to a higher rate of major hemorrhage than placebo. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583 .). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

22. ASPREE-D: Aspirin for the prevention of depression in the elderly

Author

Berk, Michael, primary, Woods, R. L., additional, Nelson, M. R., additional, Shah, R. C., additional, Reid, C. M., additional, Storey, E., additional, Fitzgerald, S. M., additional, Lockery, J. E., additional, Wolfe, R., additional, Mohebbi, M., additional, Murray, A. M., additional, Kirpach, B., additional, Grimm, R., additional, and McNeil, J. J., additional

Published
2016
Full Text
View/download PDF

23. ASPREE-D: Aspirin for the prevention of depression in the elderly.

Author

Mohebbi, M., Berk, Michael, Woods, R. L., Fitzgerald, S. M., Lockery, J. E., Wolfe, R., McNeil, J. J., Reid, C. M., Nelson, M. R., Shah, R. C., Storey, E., Murray, A. M., Kirpach, B., and Grimm, R.

Abstract

Background: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.Method: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.Results: This paper presents the rationale for the study and presents a summary of the study design.Conclusions: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

38. Rigid Polyurethane Foam (RPF) Technology for Countermine (SEA) Program - Phase 1

Author

SANDIA NATIONAL LABS ALBUQUERQUE NM, Woods, R. L., SANDIA NATIONAL LABS ALBUQUERQUE NM, and Woods, R. L.

Abstract

This Phase 1 report documents the results of one of the subtasks that was initiated under the joint Department of Energy (DOE)/Department of Defense (DoD) Memorandum of Understanding (MOU) for Countermine Warfare. The development of a foam that can neutralize mines and barriers and allow the safe passage of amphibious landing craft and vehicles was the objective of this subtask of the Sea Mine Countermeasures Technology program. This phase of the program concentrated on laboratory characterization of foam properties and field experiments with prefabricated foam blocks to determine the capability of RPF to adequately carry military traffic. It also established the flammability characteristics of the material under simulated operational conditions, extended the understanding of explosive cavity formation in RPF to include surface explosions, established the tolerance to typical military fluids, and the response to bullet impact. Many of the basic analyses required to establish the operational concept are reported. The initial field experiments were conducted at the Energetic Materials Research and Testing Center (EMRTC) of the New Mexico Institute of Mining and Technology, Socorro, NM in November 1995 through February 1996.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results